Vaccine for mycoplasma infection
Disclosed is a vaccine which has a high therapeutic effect on mycoplasma infection and is highly safe. For the purpose of developing effective therapeutic methods for mycoplasma infection, mycoplasma -mimic particles which are effective as a vaccine for mycoplasma infection are provided, and also provided are bacterium-mimic particles including common bacteria. Bacterium-mimic particles such as mycoplasma -mimic particles can be provided by producing liposome particles in which a lipid antigen specific to a pathogenic bacterium such as mycoplasma is contained as a liposome-constituting lipid component. The administration of the mycoplasma -mimic particles enables the induction of a potent immunological activity in living bodies. The mycoplasma -mimic particles can be used as an excellent vaccine for the prevention or treatment of mycoplasma infection.
1. Pathogenic bacterium-mimic particles, comprising:
liposome particles including at least one purified lipid antigen specific to a pathogenic bacterium as a liposome-constituting lipid component,
wherein the lipid component consists of the purified lipid antigen alone or a mixture of the purified lipid antigen, phospholipid and cholesterol, and
wherein the pathogenic bacterium-mimic particles can cause immune response in the immune system in an organism which is susceptible of being infected with the pathogenic bacterium.
2. Mycoplasma -mimic particles, comprising:
liposome particles including at least one purified mycoplasma -specific glycolipid antigen as a liposome-constituting lipid component,
wherein the at least one purified mycoplasma -specific glycolipid antigen is chemically or enzymatically synthesized, and then separated and purified.
3. The mycoplasma -mimic particles according to claim 2 , wherein the at least one purified mycoplasma -specific glycolipid antigen is a Mycoplasma pneumoniae -specific glycolipid antigen, or a Mycoplasma fermentans -specific glycolipid antigen.
4. The mycoplasma -mimic particles according to claim 2 , further comprising:
phosphatidyl choline, phosphoglycerol, and/or cholesterol as a second liposome-constituting lipid component.
5. The mycoplasma -mimic particles according to claim 2 , wherein the liposome-constituting lipid components containing the purified mycoplasma -specific glycolipid antigen are mixed in a solvent, and then prepared as particles under conditions in which the particle diameter is in a range of 30 to 300 nm, and 80% or more thereof is in a range of 40 to 200 nm by ultrasonic wave treatment.
6. A vaccine for prevention or treatment of a disease caused by a mycoplasma infection, comprising the mycoplasma -mimic particles according to claim 2 as an active ingredient and a pharmaceutically acceptable excipient.
7. The vaccine for prevention or treatment of a disease caused by a mycoplasma infection according to claim 6 , wherein the mycoplasma -mimic particles are Mycoplasma pneumoniae -mimic particles or Mycoplasma fermentans -mimic particles.
8. The pathogenic bacterium-mimic particles according to claim 1 , wherein the pathogenic bacterium is selected from the group consisting of Helicobacter pylori bacterium, chlamydia, rickettsia , tuberculosis bacterium, and pneumococcus.
9. The mycoplasma -mimic particles according to claim 3 , wherein the at least one purified mycoplasma -specific glycolipid antigen is selected from the group consisting of GGPL-I, GGPL-III, GGL Glc-type, and GGL Gal-type.